Halozyme Therapeutics Added to Russell 1000® Index
The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks.
'Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth,' said Dr. Helen Torley, President and CEO of Halozyme. 'The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future.'
The Russell 1000® is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the future execution of Halozyme's strategy and delivery of future sustainable growth and profitability, the durability of Halozyme's top and bottom line growth, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in the execution of Halozyme's strategy and unexpected future financial results and top and bottom line growth,. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contacts:
Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@halozyme.com
Sydney CharltonTeneo917-972-8407sydney.charlton@teneo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 hours ago
- The Sun
Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha
HONG KONG SAR - EQS Newswire - 2 July 2025 - On June 27, 2025, Uni-Bio Science Group Limited (the 'Group')grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌顏態® and the medical device brand 金因敷®. Many experts, KOLs and partners attended the event. This launch not only showcased the Group's achievements in R&D, but also marked the comprehensive layout in the 'drug, medical device and Aesthetics' field. 1、 High-end medical aesthetics: GeneQueens series At the launch, the Group unveiled the high-end series of 肌顏態® -——GeneQueensTM (Human-Sequence Triple Protein Repair & Balance Ampoule). which functions on skin repair and anti-aging. By activating cell regeneration, it helps users restore their youthful and healthy skin condition. GeneQueensTM sets a new standard for anti-aging and repair by adding three core ingredients in sufficient quantities. Skbrella FN, as a key ingredient for cell repair, can accelerate the healing of skin wounds and promote the adhesion and migration of new cells. III Collagen strongly fills the skin structure, significantly enhancing elasticity and firmness. XVII Collagen can strengthen the connection between the epidermis and dermis, and consolidate the youthful foundation of the skin. In addition, GeneQueens adopts a sterile and preservative-free formula, relying on high-purity raw materials and patented technology, providing users with an 'instant enjoyment' precise and efficient experience. Its unique formula and outstanding efficacy were highly recognized by many experts on the spot. 2、金因敷 showcased a variety of new products Meanwhile, the Group also launched several new products of its medical device brand - 金因敷®, focusing on the professional repair field of medical aesthetics. 金因敷® complies with strict clinical trials and quality inspections to ensure its safety and effectiveness. The product adopts a high-purity non-allergenic formula, which can moisturize and accelerate wound repair. It also uses an exclusive cooling technology to relieve postoperative swelling and pain, providing a professional solution for sensitive skin and post-medical procedure care. 3、The latest research data was presented at CSD2025 It is worth mentioning that 肌顏態® also showcased the research data of 'The Efficacy Study of Fibronectin in the Repair of Skin Barrier Damage for the post-medical procedure' jointly conducted with the Cosmetics Testing Center of the Dermatology Hospital of Southern Medical University in the poster area of the 30th Academic Conference of the Chinese Medical Association (CSD2025). This is not only an endorsement of the Group's research capabilities, but also provides experts and scholars in the industry with an opportunity to gain a deeper understanding of the 肌顏態® technology and products. As an annual grand event in the field of dermatology and venereology in China, CSD2025 brings together authoritative experts and scholars in dermatology across the country, presenting multi-dimensional academic achievements and exchanges of ideas. The poster area is one of the core venues of the academic annual conference. Posters are not only an important way for researchers to showcase their scientific research achievements, but also a key link in promoting the dissemination of academic ideas and the feedback of clinical practice. 4、Academic speeches by several experts Several clinical experts at the launch further recognized the significant clinical value of 肌顏態® and 金因敷®. The experts highlighted that 肌顏態®' s patented ingredient, Skbrella FN, demonstrates immense potential in improving damaged sensitive skin barriers, reducing inflammatory erythema, alleviating discomfort sensations such as burning, tightness and itching, as well as enhancing post-laser repair and healing. In the clinical observations over the past few months, many patients treated with 肌顏態® have achieved remarkable therapeutic effects. The symptoms of anesthetic allergy have been rapidly relieved, the inflammatory pigmentation post-laser has significantly improved, the skin barrier has been repaired, and the patient satisfaction rate is extremely high. 金因敷® can effectively reduce redness, swelling and pain for post-medical procedures, accelerate wound healing and shorten the recovery time. Photo 1: 肌顏態 use case sharing by Professor Shi Ge, Director of the Department of Plastic Surgery of the Sixth Affiliated Hospital of Sun Yat-sen University; Photo 2: 肌顏態 use case sharing by Professor Ge Lan, from The First Affiliated Hospital of Army Medical University; Photo 3: Fibronectin clinical trial results sharing by Professor Ye Li, Head of Cosmetics Testing Center at Dermatology Hospital of Southern Medical University; Photo 4: Mr. Du Wei, CEO of Cosmetics News & Cosmetics Business Online, analyzes cosmetics industry development trends 6、The signing ceremony reflects the market potential Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, emphasized: ' We have always adhered to the standards of biopharmaceuticals in creating skin care products. The release of GeneQueens and 金因敷 is an important milestone in building the 'Drugs, Medical device and Aesthetics' strategy and creating a full-cycle skin care solution, aiming to meet consumers' increasingly refined skin health needs. ' Furthermore, Ms. Liu Yihua, President of Global Cosmetics Group, attended the launch as an important guest. Uni-Bio Science Group and Global Cosmetics Group have jointly established a medical research co-creation biological platform. Utilizing gene-editing biosynthesis technology, the platform has launched Skbrella FN – a highly bioactive recombinant human fibronectin known as '皮優理'. The launch also witnessed a grand strategic signing ceremony. The Group has achieved in-depth cooperation with many well-known medical aesthetics chain institutions and well-known agents. This signing is not only a high recognition of the quality and market potential of GeneQueens and 金因敷®, but also a key step for the Group to accelerate commercialization and expand channels. Through strong alliances with leading channel partners, the Group will reach the core consumers and ensure the rapid release of huge commercial value. The successful holding of this launch not only marks a crucial step for the Group in medical aesthetics and medical devices, but also demonstrates the Group's in-depth layout and forward-looking vision in the 'Drugs, Medical device and Aesthetics' strategy. In the future, the Group will continue to be guided by technology and oriented towards clinical value, accelerate product innovation and technological upgrading, constantly enrich pipeline, and meet the growing market demands.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Hamilton Lane Launches First Asia-Focused Private Markets Evergreen Offering to Enable Access to Targeted Opportunities Across the Region
The Hamilton Lane Asia Private Assets Fund aims to offer private wealth investors a first-of-its-kind opportunity to tap into Asia's $3+ trillion private equity market1 Launch is the latest addition to Hamilton Lane's $11 billion2 global Evergreen Platform HONG KONG, July 1, 2025 /PRNewswire/ — Leading private markets investment firm Hamilton Lane (Nasdaq: HLNE) today announced the launch of its Asia Private Assets Fund ('HLAPA' or 'the Fund')3, a pioneering semi-liquid vehicle that aims to provide private wealth and institutional investors with diversified access to Asia's private markets landscape. HLAPA seeks to provide investors with diversified, attractive return exposure to Asia's private markets, focusing on private equity through direct investments and secondaries. By leveraging Hamilton Lane's more than 15 years of experience investing across Asia, as well as the firm's extensive regional network and established, flexible evergreen structure, the Fund aims to capitalize on Asia's macroeconomic tailwinds and deliver quality risk-adjusted returns. Key features of the Fund include: A flexible portfolio construction, allowing it to adapt to market dynamics and designed to optimize risk-adjusted returns across innovative growth investments and mature buyout deals; Access to investments alongside top-tier fund managers across Asia, including deep relationships with what Hamilton Lane believes are premiere GPs across Australia, Japan, Korea, India, Southeast Asia and China; An open-ended, flexible structure that provides immediate capital deployment without capital calls, along with lower minimum investments compared to traditional drawdown funds, monthly subscriptions and the potential for limited quarterly liquidity subject to the Fund's terms and conditions. Collwyn Tan, Co-Head of Asia Investments commented: 'Asia drives 60% of global GDP growth, much of it through a vibrant private sector, yet most private market products focus on broad global and U.S. exposure and offer limited access to Asia. HLAPA is a pioneering offering that seeks to provide wealth professionals and investors of all sizes with seamless, diversified access to Asia's compelling private asset landscape.' 'Hamilton Lane has been a global leader when it comes to expanding private market access for investors, and we are excited to announce the launch of HLAPA, a Fund that aims to provide investors with access to Asia's private market potential—from tech and growth investments to mature buyout deals. HLAPA's open-ended structure and the potential for liquidity create a compelling opportunity for investors to access high-quality private assets without the constraints of traditional drawdown funds,' SungJi Steve An, Head of Client Solutions APAC, added. The Hamilton Lane Asia Private Assets Fund is the latest addition to the firm's broader $11 billion AUM2 Evergreen Platform, which first launched in 2019 and today includes nine funds across multiple strategies. 1 As of February 2025. Source: Hamilton Lane data 2 As of May 31,20253 The first dealing date that subscriptions will be accepted from investors for APA is targeted for September 1, 2025 Disclosure This is not an offer to sell, or a solicitation of any offer to buy, any security or to enter into any agreement with Hamilton Lane or any of its affiliates. Any such offering will be made only at your request. We do not intend that any public offering will be made by us at any time with respect to any potential transaction discussed herein. Any offering or potential transaction will be made pursuant to separate documentation negotiated between us, which will supersede entirely the information contained herein. About Hamilton LaneHamilton Lane (Nasdaq: HLNE) is one of the largest private markets investment firms globally, providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 760 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has approximately $958 billion in assets under management and supervision, composed of more than $138 billion in discretionary assets and more than $819 billion in non-discretionary assets, as of March 31, 2025. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit our website or follow us on LinkedIn.
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Medline named Prime Vendor by Wachusett Healthcare
East Coast provider of skilled nursing and rehabilitative services taps into Medline's supply chain and clinical portfolio NORTHFIELD Ill., July 1, 2025 /PRNewswire/ — Medline today announced a new Prime Vendor agreement with skilled nursing and rehabilitative services provider Wachusett Healthcare. As part of the agreement, Wachusett Healthcare's facilities will choose from Medline's extensive portfolio of medical products and supplies, including Medline's skin health products. The East Coast-based organization will also receive accompanying skin health guidelines, educational programs and evidence-based online training courses for continuing education in skin and wound care via Medline University, as well as in-servicing through Medline's team of clinicians and skin health specialists. 'At Wachusett Healthcare, we are always striving to enhance the quality of care and operational excellence across our facilities. Our partnership with Medline represents a strategic alignment with a leader in healthcare supply chain solutions,' said Steven Vera, Chief Executive Officer, Wachusett Healthcare. 'It will allow us to streamline our procurement process, ensure consistent access to high-quality products, and ultimately support our staff in delivering exceptional care to our residents.' Said Brendon Anderson, corporate accounts director for Medline Long-Term Care: 'Wachusett Healthcare is committed to providing a safe and compassionate care environment. We will support them in their commitment by ensuring a consistent supply of high-quality medical products that positively impacts Wachusett's care delivery needs. We are honored to be their Prime Vendor.' Learn how Medline works with long-term care providers to improve clinical, financial and operational outcomes at About MedlineMedline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 43,000 people worldwide and operates in more than 100 countries and territories. To learn more about how Medline makes healthcare run better, visit FacebookTwitterLinkedInYouTube
